http://orcid.org/0000-0003-1544-458X
Citations (74)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Rachel K. Landis, Jonathan S. Levin, Brendan Saloner, Adam J. Gordon, Andrew W. Dick, Tisamarie B. Sherry, Douglas L. Leslie, Mark Sorbero & Bradley D. Stein. (2022) Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. Substance Abuse 43:1, pages 1057-1071.
Read now
Read now
Caroline Geiger, Rosanna Smart & Bradley D. Stein. (2020) Who receives naloxone from emergency medical services? Characteristics of calls and recent trends. Substance Abuse 41:3, pages 400-407.
Read now
Read now
Articles from other publishers (72)
Utsha G. Khatri, Max Jordan Nguemeni Tiako, Abeselom Gebreyesus, Andre Reid, Sara F. Jacoby & Eugenia C. South. (2023) “A Lack of Empathy:” A qualitative study of Black people seeking treatment for opioid use disorder. SSM - Qualitative Research in Health 4, pages 100298.
Crossref
Crossref
Saharnaz Nedjat, Yun Wang, Khashayar Eshtiaghi & Marc Fleming. (2023) Is there a disparity in medications for opioid use disorder based on race/ethnicity and gender? A systematic review and meta-analysis. Research in Social and Administrative Pharmacy.
Crossref
Crossref
Allison Perry, Katherine Wheeler-Martin, Deborah S. Hasin, Kelly Terlizzi, Zachary L. Mannes, Victoria Jent, Tarlise N. Townsend, John R. PamplinIIII, Stephen Crystal, Silvia S. Martins, Magdalena Cerdá & Noa Krawczyk. (2023) Utilization and disparities in medication treatment for opioid use disorder among patients with comorbid opioid use disorder and chronic pain during the COVID-19 pandemic. Drug and Alcohol Dependence 253, pages 111023.
Crossref
Crossref
Olivia K. Golan, Flora Sheng, Andrew W. Dick, Mark Sorbero, Daniel J. Whitaker, Barbara Andraka-Christou, Therese Pigott, Adam J. Gordon & Bradley D. Stein. (2023) Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009–2018. Drug and Alcohol Dependence Reports 9, pages 100193.
Crossref
Crossref
Jennifer Miles, Peter Treitler, Richard Hermida, Amesika N. Nyaku, Kosali Simon, Sumedha Gupta, Stephen Crystal & Hillary Samples. (2023) Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries. Drug and Alcohol Dependence 252, pages 110963.
Crossref
Crossref
Abhimanyu Sud, Kellia Chiu, Joseph Friedman & Julie Dupouy. (2023) Buprenorphine deregulation as an opioid crisis policy response - A comparative analysis between France and the United States. International Journal of Drug Policy 120, pages 104161.
Crossref
Crossref
Winnie Chi, Binh NguyenQinli MaDarrell GrayEric BaillyAnthony LoSassoShantanu Agrawal. (2023) Impact of COVID-19 on Behavioral Health Services Use Among Medicaid Enrollees with Chronic Behavioral Needs by Race and Ethnicity. Population Health Management.
Crossref
Crossref
Trevor Magee, Caleb Peters, Samuel M. Jacobsen, Danya Nees, Bryan Dunford, Alicia Ito Ford & Matt Vassar. (2023) Inequities in the treatment of opioid use disorder: A scoping review. Journal of Substance Use and Addiction Treatment 152, pages 209082.
Crossref
Crossref
Anna Conway, Noa Krawczyk, Frances McGaffey, Sheri Doyle, Vanessa Baaklini, Alison D. Marshall, Carla Treloar, Corey S. Davis, Samantha Colledge-Frisby, Jason Grebely & Magdalena Cerdá. (2023) Typology of laws restricting access to methadone treatment in the United States: A latent class analysis. International Journal of Drug Policy 119, pages 104141.
Crossref
Crossref
Ryan P. McCormack, John Rotrosen, Phoebe Gauthier, Gail D’Onofrio, David A. Fiellin, Lisa A. Marsch, Patricia Novo, David Liu, E. Jennifer Edelman, Sarah Farkas, Abigail G. Matthews, Caroline Mulatya, Dagmar Salazar, Jeremy Wolff, Randolph Knight, William Goodman, Joseph Williams & Kathryn Hawk. (2023) Implementing Programs to Initiate Buprenorphine for Opioid Use Disorder Treatment in High-Need, Low-Resource Emergency Departments: A Nonrandomized Controlled Trial. Annals of Emergency Medicine 82:3, pages 272-287.
Crossref
Crossref
Jason B Gibbons, Samantha J Harris, Keisha T Solomon, Olivia Sugarman, Carlos Hardy & Brendan Saloner. (2023) Increasing overdose deaths among Black Americans: a review of the literature. The Lancet Psychiatry 10:9, pages 719-726.
Crossref
Crossref
Dominique Bulgin, Stephen W. Patrick, Tamarra McElroy, Elizabeth McNeer, William D. Dupont & Velma McBride Murry. (2023) Patient and Community Factors Affecting Treatment Access for Opioid Use Disorder. Obstetrics & Gynecology 142:2, pages 339-349.
Crossref
Crossref
Chris Miller-Rosales, Nancy E. Morden, Mary F. Brunette, Susan H. Busch, John B. Torous & Ellen R. Meara. (2023) Provision of Digital Health Technologies for Opioid Use Disorder Treatment by US Health Care Organizations. JAMA Network Open 6:7, pages e2323741.
Crossref
Crossref
Wesley C. Holland, Fangyong Li, Bidisha Nath, Molly M. Jeffery, Maria Stevens, Edward R. Melnick, James D. Dziura, Hazar Khidir, Rachel M. Skains, Gail D'Onofrio & William E. SoaresIIIIII. (2023) Racial and ethnic disparities in emergency department–initiated buprenorphine across five health care systems. Academic Emergency Medicine 30:7, pages 709-720.
Crossref
Crossref
Michael A. Incze, David Chen, Patrick Galyean, Elisabeth R. Kimball, Laura Stolebarger, Susan Zickmund & Adam J. Gordon. (2023) Examining the Primary Care Experience of Patients With Opioid Use Disorder: A Qualitative Study. Journal of Addiction Medicine 17:4, pages 401-406.
Crossref
Crossref
Shikhar Shrestha, Megan R. Lindstrom, Daniel Harris, Peter Rock, Sumeeta Srinivasan, Jennifer C. Pustz, Ric Bayly & Thomas J. Stopka. (2023) Spatial access to buprenorphine-waivered prescribers in the HEALing communities study: Enhanced 2-step floating catchment area analyses in Massachusetts, Ohio, and Kentucky. Journal of Substance Use and Addiction Treatment 150, pages 209077.
Crossref
Crossref
Adam J. Gordon, Andrew J. Saxon, Stefan Kertesz, Jessica J. Wyse, Ajay Manhapra, Lewei A. Lin, Wei Chen, Jared Hansen, Derek Pinnell, Tina Huynh, Jacob D. Baylis, Francesca E. Cunningham, Udi E. Ghitza, Gavin Bart, Hong Yu & Brian C. Sauer. (2023) Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration. Drug and Alcohol Dependence 248, pages 109902.
Crossref
Crossref
Megan S. Schuler, Brendan Saloner, Adam J. Gordon, Andrew W. Dick & Bradley D. Stein. (2023) National Trends in Buprenorphine Treatment for Opioid Use Disorder From 2007 to 2018. Substance Abuse, pages 088970772311795.
Crossref
Crossref
Michael L. Barnett, Ellen Meara, Terri LewinsonBrianna HardyDeanna ChynMoraa OnsandoHaiden A. HuskampAteev MehrotraNancy E. Morden. (2023) Racial Inequality in Receipt of Medications for Opioid Use Disorder. New England Journal of Medicine 388:19, pages 1779-1789.
Crossref
Crossref
Bradley D. Stein, Brendan K. Saloner, Olivia K. Golan, Barbara Andraka-Christou, Christina M. Andrews, Andrew W. Dick, Corey S. Davis, Flora Sheng & Adam J. Gordon. (2023) Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment. JAMA Health Forum 4:5, pages e231102.
Crossref
Crossref
Tami L. Mark, La Sonya A. Goode, Gary McMurtrie, Lara Weinstein & Rebecca J. Perry. (2023) Improving Research on Racial Disparities in Access to Medications to Treat Opioid Use Disorders. Journal of Addiction Medicine 17:3, pages 249-257.
Crossref
Crossref
Jarratt D. Pytell, Geetanjali Chander, Ashish P. Thakrar, S. Michelle Ogunwole & Emma E. McGinty. (2022) Does a Survivorship Model of Opioid Use Disorder Improve Public Stigma or Policy Support? A General Population Randomized Experiment. Journal of General Internal Medicine 38:7, pages 1638-1646.
Crossref
Crossref
Christian Heidbreder, Paul J. Fudala & Mark K. Greenwald. (2023) History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug and Alcohol Dependence Reports 6, pages 100133.
Crossref
Crossref
Svetla Slavova, Patricia R. Freeman, Peter Rock, Candace Brancato, Sarah Hargrove, Madison Liford, Dana Quesinberry & Sharon L. Walsh. (2022) Changing Trends in Drug Overdose Mortality in Kentucky: An Examination of Race and Ethnicity, Age, and Contributing Drugs, 2016-2020. Public Health Reports 138:1, pages 131-139.
Crossref
Crossref
Jawad M. Husain, Devin Cromartie, Emma Fitzelle-Jones, Annelise Brochier, Christina P.C. Borba & Cristina Montalvo. (2023) A qualitative analysis of barriers to opioid agonist treatment for racial/ethnic minoritized populations. Journal of Substance Abuse Treatment 144, pages 108918.
Crossref
Crossref
Andrew Anderson, Brigham Walker, Yixue Shao, Thomas A. LaVeist & Kevin Callison. (2022) Racial and Ethnic Disparities in Medication-Assisted Treatment: Evidence from Louisiana Medicaid During the COVID-19 Pandemic. Journal of General Internal Medicine 38:1, pages 266-268.
Crossref
Crossref
ALEXANDER D. McCOURT, SARAH A. WHITE, SACHINI BANDARA, THEO SCHALL, DAISY J. GOODMAN, ESITA PATEL & EMMA E. McGINTY. (2022) Development and Implementation of State and Federal Child Welfare Laws Related to Drug Use in Pregnancy. The Milbank Quarterly 100:4, pages 1076-1120.
Crossref
Crossref
Michael DiNardi, William L. Swann & Serena Y. Kim. (2022) Racial/ethnic residential segregation and the availability of opioid and substance use treatment facilities in US counties, 2009–2019. SSM - Population Health 20, pages 101289.
Crossref
Crossref
Lauren R. Gilbert, Steven Starks, Johnathan Gray, Lorraine R. Reitzel & Ezemenari M. Obasi. (2022) Exploring the provider and organization level barriers to medication for opioid use disorder treatment for Black Americans: A study protocol. Public Health in Practice 4, pages 100308.
Crossref
Crossref
Rachel K. Landis, Isaac Opper, Brendan Saloner, Adam J. Gordon, Douglas L. Leslie, Mark Sorbero & Bradley D. Stein. (2022) Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies. Drug and Alcohol Dependence 241, pages 109669.
Crossref
Crossref
Jonathan H. Cantor, Maria DeYoreo, Russell Hanson, Aaron Kofner, David Kravitz, Adrian Salas, Bradley D. Stein & Kandice A. Kapinos. (2022) Patterns in Geographic Distribution of Substance Use Disorder Treatment Facilities in the US and Accepted Forms of Payment From 2010 to 2021. JAMA Network Open 5:11, pages e2241128.
Crossref
Crossref
Caroline A. King, Ryan Cook, P. Todd Korthuis, Dennis McCarty, Cynthia D. Morris & Honora Englander. (2022) Expanding Inpatient Addiction Consult Services Through Accountable Care Organizations for Medicaid Enrollees: A Modeling Study. Journal of Addiction Medicine 16:5, pages 570-576.
Crossref
Crossref
Jonathan S. Levin, Rachel K. Landis, Mark Sorbero, Andrew W. Dick, Brendan Saloner & Bradley D. Stein. (2022) Differences in buprenorphine treatment quality across physician provider specialties. Drug and Alcohol Dependence 237, pages 109510.
Crossref
Crossref
Honora Englander, Amy Jones, Noa Krawczyk, Alisa Patten, Timothy Roberts, P. Todd Korthuis & Jennifer McNeely. (2022) A Taxonomy of Hospital-Based Addiction Care Models: a Scoping Review and Key Informant Interviews. Journal of General Internal Medicine 37:11, pages 2821-2833.
Crossref
Crossref
Qinyun Lin, Marynia Kolak, Beth Watts, Luc Anselin, Harold Pollack, John Schneider & Bruce Taylor. (2022) Individual, interpersonal, and neighborhood measures associated with opioid use stigma: Evidence from a nationally representative survey. Social Science & Medicine 305, pages 115034.
Crossref
Crossref
Thuy Nguyen, Engy Ziedan, Kosali Simon, Jennifer Miles, Stephen Crystal, Hillary Samples & Sumedha Gupta. (2022) Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic. JAMA Network Open 5:6, pages e2214765.
Crossref
Crossref
Monica Rivera Mindt, Kelly Coulehan, Maral Aghvinian, Travis M. Scott, James Patrick Olsen, Chinazo O. Cunningham, Franchesca Arias & Julia H. Arnsten. (2022) Underrepresentation of diverse populations and clinical characterization in opioid agonist treatment research: A systematic review of the neurocognitive effects of buprenorphine and methadone treatment. Journal of Substance Abuse Treatment 135, pages 108644.
Crossref
Crossref
Sarah E. Wakeman. (2022) Opioid Use Disorder Diagnosis and Management. NEJM Evidence 1:4.
Crossref
Crossref
Susan Regan, Sydney Howard, Elizabeth Powell, Alister Martin, Sayon Dutta, Bryan D. Hayes, Benjamin A. White, Dawn Williamson, Laura Kehoe, Ali S. Raja & Sarah E. Wakeman. (2022) Emergency Department-initiated Buprenorphine and Referral to Follow-up Addiction Care: A Program Description. Journal of Addiction Medicine 16:2, pages 216-222.
Crossref
Crossref
Anna Beth Parlier-Ahmad, Maja Radic, Dace S. Svikis & Caitlin E. Martin. (2022) Short communication: Relationship between social determinants and opioid use disorder treatment outcomes by gender. Drug and Alcohol Dependence 232, pages 109337.
Crossref
Crossref
Pia M. Mauro, Sarah Gutkind, Erin M. Annunziato & Hillary Samples. (2022) Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019. JAMA Network Open 5:3, pages e223821.
Crossref
Crossref
Jannat SainiBreah JohnsonDanya M. Qato. (2022) Self-Reported Treatment Need and Barriers to Care for Adults With Opioid Use Disorder: The US National Survey on Drug Use and Health, 2015 to 2019. American Journal of Public Health 112:2, pages 284-295.
Crossref
Crossref
Chandler McClellan, Asako Moriya & Kosali Simon. (2022) Users of retail medications for opioid use disorders faced high out-of-pocket prescription spending in 2011–2017. Journal of Substance Abuse Treatment 132, pages 108645.
Crossref
Crossref
Dominic Hodgkin, Constance Horgan & Gavin Bart. (2021) Financial sustainability of payment models for office-based opioid treatment in outpatient clinics. Addiction Science & Clinical Practice 16:1.
Crossref
Crossref
Matthew Robbins, Rachel Haroz, Anthony Mazzarelli, David ClementsIVIV, Christopher W. Jones & Matthew Salzman. (2021) Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study. Journal of Substance Abuse Treatment 130, pages 108405.
Crossref
Crossref
Shichao Tang, Jennifer L. Matjasko, Christopher R. Harper, Whitney L. Rostad, Katie A. Ports, Andrea E. Strahan & Curtis Florence. (2021) Impact of Medicaid expansion and methadone coverage as a medication for opioid use disorder on foster care entries during the opioid crisis. Children and Youth Services Review 130, pages 106249.
Crossref
Crossref
Jonathan Cantor, Andrew W. Dick, Rebecca Haffajee, Megan F. Pera, Dena M. Bravata, Bradley D. Stein & Christopher M. Whaley. (2021) Use of buprenorphine for those with employer-sponsored insurance during the initial phase of the COVID-19 pandemic. Journal of Substance Abuse Treatment 129, pages 108384.
Crossref
Crossref
Jonathan Cantor, David Kravitz, Mark Sorbero, Barbara Andraka-Christou, Christopher Whaley, Kathryn Bouskill & Bradley D. Stein. (2021) Trends in visits to substance use disorder treatment facilities in 2020. Journal of Substance Abuse Treatment 127, pages 108462.
Crossref
Crossref
Noa Krawczyk, Arthur Robin Williams, Brendan Saloner & Magdalena Cerdá. (2021) Who stays in medication treatment for opioid use disorder? A national study of outpatient specialty treatment settings. Journal of Substance Abuse Treatment 126, pages 108329.
Crossref
Crossref
Barbara Andraka-Christou. (2021) Addressing Racial And Ethnic Disparities In The Use Of Medications For Opioid Use Disorder. Health Affairs 40:6, pages 920-927.
Crossref
Crossref
Michaela Mitchell, Kameron Shee, Kelly Champlin, Alison C. Essary & Matthew Evans. (2021) Opioid use disorder and COVID-19. JAAPA 34:6, pages 1-4.
Crossref
Crossref
Laura J. Faherty, Sara HeinsAshley M. KranzBradley D. Stein. (2021) Postpartum Treatment for Substance Use Disorder Among Mothers of Infants with Neonatal Abstinence Syndrome and Prenatal Substance Exposure. Women's Health Reports 2:1, pages 163-172.
Crossref
Crossref
Megan S. Schuler, Andrew W. Dick & Bradley D. Stein. (2021) Growing racial/ethnic disparities in buprenorphine distribution in the United States, 2007-2017. Drug and Alcohol Dependence 223, pages 108710.
Crossref
Crossref
Kelly E. Anderson, Brendan Saloner, Julia Eckstein, Christine E. Chaisson, Sarah H. Scholle, Lauren Niles, Sydney Dy & G. Caleb Alexander. (2021) Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder. Medical Care 59:5, pages 393-401.
Crossref
Crossref
Megan S. Schuler, Terry L. Schell & Eunice C. Wong. (2021) Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999–2018. Drug and Alcohol Dependence 221, pages 108588.
Crossref
Crossref
Max Jordan Nguemeni Tiako. (2021) Addressing racial & socioeconomic disparities in access to medications for opioid use disorder amid COVID-19. Journal of Substance Abuse Treatment 122, pages 108214.
Crossref
Crossref
Mohammad S. Jalali, Michael Botticelli, Rachael C. Hwang, Howard K. Koh & R. Kathryn McHugh. (2020) The opioid crisis: a contextual, social-ecological framework. Health Research Policy and Systems 18:1.
Crossref
Crossref
Bronwyn S. Bedrick, Carly O’Donnell, Christine M. Marx, Hayley Friedman, Ebony B. Carter, Molly J. Stout & Jeannie C. Kelly. (2020) Barriers to accessing opioid agonist therapy in pregnancy. American Journal of Obstetrics & Gynecology MFM 2:4, pages 100225.
Crossref
Crossref
Quianta Moore, Patrick S. Tennant & Lisa R. Fortuna. (2020) Improving Research Quality to Achieve Mental Health Equity. Psychiatric Clinics of North America 43:3, pages 569-582.
Crossref
Crossref
Melanie S. Askari, Silvia S. Martins & Pia M. Mauro. (2020) Medication for opioid use disorder treatment and specialty outpatient substance use treatment outcomes: Differences in retention and completion among opioid-related discharges in 2016. Journal of Substance Abuse Treatment 114, pages 108028.
Crossref
Crossref
Shaheen Kurani, Rozalina Grubina McCoy, Jonathan Inselman, Molly Moore Jeffery, Sagar Chawla, Lila J Finney Rutten, Rachel Giblon & Nilay D Shah. (2020) Place, poverty and prescriptions: a cross-sectional study using Area Deprivation Index to assess opioid use and drug-poisoning mortality in the USA from 2012 to 2017. BMJ Open 10:5, pages e035376.
Crossref
Crossref
Rhiannon Bath, Tanner Bucholz, Amy F. Buros, Darshan Singh, Kirsten E. Smith, Charles A. Veltri & Oliver Grundmann. (2020) Self-reported Health Diagnoses and Demographic Correlates With Kratom Use: Results From an Online Survey. Journal of Addiction Medicine 14:3, pages 244-252.
Crossref
Crossref
George Pro, Jeff Utter, Shane Haberstroh & Julie A. Baldwin. (2020) Dual mental health diagnoses predict the receipt of medication-assisted opioid treatment: Associations moderated by state Medicaid expansion status, race/ethnicity and gender, and year. Drug and Alcohol Dependence 209, pages 107952.
Crossref
Crossref
William C. Goedel, Aaron Shapiro, Magdalena Cerdá, Jennifer W. Tsai, Scott E. Hadland & Brandon D. L. Marshall. (2020) Association of Racial/Ethnic Segregation With Treatment Capacity for Opioid Use Disorder in Counties in the United States. JAMA Network Open 3:4, pages e203711.
Crossref
Crossref
Elisha M. Wachman. (2020) How Might Maternal Poverty Impact the Course of Neonatal Opioid Withdrawal Syndrome?. Journal of Addiction Medicine 14:2, pages 93-94.
Crossref
Crossref
Amy E. Caruso Brown. (2020) Treating Addiction as a Terminal Disease. New England Journal of Medicine 382:3, pages 207-209.
Crossref
Crossref
Amanda J. Abraham, Christina M. Andrews, Samantha J. Harris & Peter D. Friedmann. (2020) Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA. Neurotherapeutics 17:1, pages 55-69.
Crossref
Crossref
Ryan Marino, Aaron Landau, Michael Lynch, Clifton Callaway & Brian Suffoletto. (2019) Do electronic health record prompts increase take‐home naloxone administration for emergency department patients after an opioid overdose?. Addiction 114:9, pages 1575-1581.
Crossref
Crossref
Heather J. Jackson & Cristina M. Lopez. (2018) Utilization of the Nurse Practitioner Role to Combat the Opioid Crisis. The Journal for Nurse Practitioners 14:10, pages e213-e216.
Crossref
Crossref
Tom MunyerRichard DeBenedetto & Sarah Luttrell. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
Tom MunyerRichard DeBenedetto & Sarah Luttrell. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.
Tom Munyer. 2017. PharmacotherapyFirst: A Multimedia Learning Resource. PharmacotherapyFirst: A Multimedia Learning Resource.